HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beautycounter-Led Coalition Lobbies For Tighter Cosmetics Regulations

This article was originally published in The Rose Sheet

Executive Summary

The beauty industry do-gooder returned to Washington Sept. 12 with 15 other brands in tow, pressing lawmakers for a hearing on the proposed Personal Care Products Safety Act.

You may also be interested in...



Amyris Inks Deal For Third Clean Beauty Brand; Inter Parfums’ Third Quarter; Beauty News In Brief

Amyris plans to launch new Rose Inc. cosmetics in the third quarter of 2021. “We believe cosmetics to be the next opportunity for us to transform to clean,” says Amyris CEO John Melo. News in brief.

Unilever Names New CEO; Sexy Hair’s $2.3m ‘Sulfate-Free’ Settlement; More Cosmetics News In Brief

Henkel’s Sexy Hair Concepts and Ulta will settle with plaintiffs over alleged “sulfate-free” deception, to the tune of $2.3m; Unilever’s Dermalogica is suing Target for unauthorized selling of diverted products. More cosmetics news in brief.

Cosmetic Safety Crusader Beautycounter Scores Funding Boost

A reported $65m financing round led by Mousse Partners will drive development of a more robust omni-channel Beautycounter business and support technology and marketing initiatives, according to the Los Angeles-area startup. Investors see Beautycounter as a "visionary" trendsetter with its ingredient safety focus.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121192

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel